Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Selected Advanced NSCLC
NCT00730925Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Jun 2008; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00730925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00730925.